

## RESEARCH

### BOB Economics Research | Weekly Wrap

India's GDP and fiscal health in focus

### BOB Economics Research | Q1FY21 GDP

Investment and consumption drive record fall in GDP

### Media & Entertainment

Unlock 4.0: Cinema shutdown extended to September

## SUMMARY

### India Economics: Weekly Wrap

Global 10Y yields went up as macro data showed further improvement in economic activity: China's industrial profits, US durable goods and new home sales. US Fed Chair introduced a new inflation targeting policy which will allow Fed to keep lower interest rates for longer. DXY fell by 0.9%. INR rose by 1.9% supported by FPI inflows. India's 10Y yield rose by 5bps despite RBI's operation Twist due to accelerating inflation and elevated fiscal deficit. Markets look forward to Q1FY21 GDP and government's fiscal numbers.

[Click here for the full report.](#)

### India Economics: Q1FY21 GDP

India's GDP growth in Q1FY21 contracted by 23.9%. Manufacturing led the decline at 39.3% followed by services at 20.6%. The only beacon of light was agriculture output which increased by 3.4%. Counter cyclical fiscal policy was visible with 16.4% jump in government consumption. However, private consumption and investment spending fell by 26.7% and 47.1% respectively. With a higher than anticipated fall in Q1 GDP and localized lockdowns in Q2 continuing, we now expect GDP to contract by 6.8% in FY21 (5% earlier).

[Click here for the full report.](#)

## TOP PICKS

### LARGE-CAP IDEAS

Company	Rating	Target
<a href="#">Bajaj Finance</a>	Buy	4,000
<a href="#">Cipla</a>	Buy	850
<a href="#">GAIL</a>	Buy	155
<a href="#">Petronet LNG</a>	Buy	310
<a href="#">Tech Mahindra</a>	Buy	780

### MID-CAP IDEAS

Company	Rating	Target
<a href="#">Alkem Labs</a>	Buy	3,600
<a href="#">Chola Investment</a>	Buy	280
<a href="#">Laurus Labs</a>	Buy	1,200
<a href="#">Transport Corp</a>	Buy	270
<a href="#">Mahanagar Gas</a>	Sell	750

Source: BOBCAPS Research

## DAILY MACRO INDICATORS

Indicator	Current	2D (%)	1M (%)	12M (%)
US 10Y yield (%)	0.72	(3bps)	14bps	(78bps)
India 10Y yield (%)	6.14	(1bps)	29bps	(42bps)
USD/INR	73.40	0.6	1.9	(2.8)
Brent Crude (US\$/bbl)	45.05	(0.1)	4.2	(25.5)
Dow	28,654	0.6	8.6	8.5
Shanghai	3,404	1.6	5.4	17.9
Sensex	39,467	0.9	2.5	5.7
<b>India FII (US\$ mn)</b>	<b>27 Aug</b>	<b>MTD</b>	<b>CYTD</b>	<b>FYTD</b>
FII-D	(177.7)	(274.7)	(14,802.3)	(5,042.8)
FII-E	192.7	6,350.9	5,062.7	11,665.6

Source: Bank of Baroda Economics Research

## BOBCAPS Research

research@bobcaps.in



## Media & Entertainment

After nearly six months of shutdown, movie halls in India were denied permission to reopen in September under the new Unlock 4.0 guidelines issued by the Ministry of Home Affairs (MHA) on 29 August. This contrasts with widespread expectations of reopening among the exhibitor fraternity. The MHA guidelines, however, allow open air theatres to function after 21 September.

[Click here](#) for the full report.

**WEEKLY WRAP**

31 August 2020

**India's GDP and fiscal health in focus**

**Global 10Y yields went up as macro data showed further improvement in economic activity: China's industrial profits, US durable goods and new home sales. US Fed Chair introduced a new inflation targeting policy which will allow Fed to keep lower interest rates for longer. DXY fell by 0.9%. INR rose by 1.9% supported by FPI inflows. India's 10Y yield rose by 5bps despite RBI's operation Twist due to accelerating inflation and elevated fiscal deficit. Markets look forward to Q1FY21 GDP and government's fiscal numbers.**

Sameer Narang | Sonal Badhan

chief.economist@bankofbaroda.com

**Markets**

- **Bonds:** Global long end yields closed higher. US 10Y yield rose by 9bps (0.72%) supported by improving economic outlook even as US Fed shifted policy mandate to average inflation targeting. This implies lower rates for longer. Crude prices rose by 1.6% (US \$ 45/bbl) due to likely impact of hurricane 'Laura' in the Gulf of Mexico. India's 10Y yield rose by 5bps (6.14%) owing to fiscal and inflationary concerns. System liquidity surplus was at Rs 4tn against Rs 3.6tn in the previous week.
- **Currency:** Global currencies closed higher against US\$ this week. DXY fell by 0.9% as Fed Chair announced a shift in its inflation targeting signalling that ultra-low rates will continue in the medium-term. GBP rose by 2% to more than 2-year high as BoE Governor hinted at further stimulus to support the economy. INR appreciated sharply by 1.9% in the week to its highest since Mar'20 supported by FII equity inflows of US\$ 793mn.
- **Equity:** Barring FTSE and Nikkei, other global indices ended higher this week led by improving global macro indicators (China's industrial profits, US home sales) and Fed's shift indicating lower rates for long. Sensex (2.7%) surged the most, posting its biggest weekly gain in a month led by banking and real estate stocks. This was followed by Dow and Dax gaining by 2.6% and 2.1% respectively.
- **Upcoming key events:** In the current week, markets will closely watch manufacturing and services PMIs of all major economies. In addition, US and Germany's factory orders and US unemployment rate will also be released. On the domestic front, Q1FY21 GDP print, core industrial index and fiscal data are due for release today.



## Q1FY21 GDP

31 August 2020

**Investment and consumption drive record fall in GDP**

India's GDP growth in Q1FY21 contracted by 23.9%. Manufacturing led the decline at 39.3% followed by services at 20.6%. The only beacon of light was agriculture output which increased by 3.4%. Counter cyclical fiscal policy was visible with 16.4% jump in government consumption. However, private consumption and investment spending fell by 26.7% and 47.1% respectively. With a higher than anticipated fall in Q1 GDP and localized lockdowns in Q2 continuing, we now expect GDP to contract by 6.8% in FY21 (5% earlier).

Sameer Narang

Dipanwita Mazumdar | Aditi Gupta

chief.economist@bankofbaroda.com

**Investment and consumption see sharp declines:** India's GDP contracted sharply by 23.9% in Q1FY21 (our estimate: 18.3%) led by 39.3% decline in manufacturing and 20.6% decline in services activity. Agriculture output increased by 3.4%. Government consumption too stood up at 16.4% in Q1. However, private consumption was subdued with a contraction of 26.7%. Investment demand (GFCF) fell by 47.1% (6.5% decline in Q4). Exports too contracted by 19.8% versus 8.5% contraction in Q4 as external demand was weak. Imports fell by 40.4% in Q1 on the back of lower domestic demand.

**Construction and trade drive GVA lower:** GVA contracted by 22.8% in Q1FY21 compared with increase of 3% in Q4FY20. Construction sector reported a sharp fall of 50.3% (2.2% decline in Q4), followed by trade, hotels, transport and communication with a decline of 47% (increase of 2.6% in Q4). Manufacturing and mining output fell by 39.3% and 23.3% respectively. While government consumption increased, public administration and defence spending fell by 10.3%. Apart from this quarter, the two series have a correlation of 0.88 in the current series. Hence, there may be a case of revision in either one of them.

**Outlook for FY21:** Since the last quarter, economic recovery has picked up. For instance, infra sector contraction in Jul'20 is 9.6% compared with a decline of 24.3% in Q1FY21. Merchandise exports have fallen by 10.2% in Jul'20 compared with a 19.8% decline in exports of goods and services in Q1. Imports have also recovered. Vehicle output, rail freight, E-way bills and other high frequency indicators are also pointing out to a recovery. However, the extent of contraction in Q1 and gradual pace of recovery on the back of continued lockdowns suggests that GVA will now contract by 6.8% in FY21 with downside risks to our estimates depending upon the duration/ spread of the pandemic.

**KEY HIGHLIGHTS**

- GDP contracted sharply by 23.9% in Q1FY21 led by sharp fall in consumption and investment.
- Government spending was a positive.
- On the supply side, manufacturing fell the most. Agriculture contributed positively.




**MEDIA & ENTERTAINMENT**

31 August 2020

## Unlock 4.0: Cinema shutdown extended to September

**Cinema exhibitors stymied again:** After nearly six months of shutdown, movie halls in India were denied permission to reopen in September under the new Unlock 4.0 guidelines issued by the Ministry of Home Affairs (MHA) on 29 August. This contrasts with widespread expectations of reopening among the exhibitor fraternity. The MHA guidelines, however, allow open air theatres to function after 21 September.

**Multiplex leaders have adequate liquidity:** PVR (PVRL) has recently completed its Rs 3bn rights issue, whereas Inox Leisure (INOL) has raised Rs 1bn through sale of treasury shares. These funds should suffice to sustain operations for the next few months, even if the lockdown extends beyond September. Our estimates bake in screen reopening in October.

**Smaller players face existential threat:** Unlike large cinema exhibitors, single screens and smaller, regional multiplex operators with limited access to external capital are already falling prey to the extended lockdown. Per a [media article](#), 10-12% of screens in the country have downed shutters permanently, including prominent single-screen theaters such as Central Plaza in Mumbai and AVM Rajeswari and Maharani in Chennai. This corroborates our view that the lockdown could hasten consolidation in favour of large multiplexes.

**New content witnessing strong response globally:** ‘Tenet’, the first big-ticket release in the pandemic era, made a strong start grossing US\$ 53mn since its release on 26 August in 41 countries. This is impressive considering that it is yet to open in key markets of the US and China. New Chinese movie ‘The Eight Hundred’ grossed a robust US\$ 277mn within 10 days of release, underscoring the sturdy recovery in China’s box office – the first major market to reach pre-Covid levels in just 4-5 weeks since reopening.

Strong consumer response to new content suggests large screens retain their appeal amidst a digital boom. Further, Tenet’s release in India may help attract patrons to theatres when screens reopen, at a time when Bollywood content appears to be depleted.

**Reiterate preference for INOL:** We continue to prefer INOL over PVRL due to its better balance sheet, lower fixed cost burden and improvement in operating parameters, as highlighted in our recent [sector initiation report](#). Delay in screen opening may, however, weigh on these stocks in the near term.

Sayan Das Sharma

research@bobcaps.in

---

### RECOMMENDATION SNAPSHOT

Ticker	Target	Rating
INOL IN	330	BUY
PVRL IN	1,220	ADD

Target in Rupees



## Disclaimer

### Recommendations and Absolute returns (%) over 12 months

**BUY** – Expected return >+15%

**ADD** – Expected return from >+5% to +15%

**REDUCE** – Expected return from -5% to +5%

**SELL** – Expected return <-5%

**Note:** Recommendation structure changed with effect from 1 January 2018 (Hold rating discontinued and replaced by Add / Reduce)

### Rating distribution

As of 31 August 2020, out of 100 rated stocks in the BOB Capital Markets Limited (BOBCAPS) coverage universe, 48 have BUY ratings, 21 have ADD ratings, 11 are rated REDUCE and 20 are rated SELL. None of these companies have been investment banking clients in the last 12 months.

### Analyst certification

Each of the analysts mentioned in this research report certify, with respect to the sections of the report for which they are responsible, that (1) all of the views expressed in this report accurately reflect his/her personal views about the subject company or companies and its or their securities, and (2) no part of his/her compensation was, is, or will be, directly or indirectly, related to the specific recommendation(s) or view(s) in this report. Analysts are not registered as research analysts by FINRA and are not associated persons of BOBCAPS.

### Important disclosures

This product is a compilation of previously published research notes. To view the complete report along with the associated Analyst certifications and Company-specific disclosures, please click on the hyperlink accompanying each excerpt.

### General disclaimers

BOBCAPS is engaged in the business of Institutional Stock Broking and Investment Banking. BOBCAPS is a member of the National Stock Exchange of India Limited and BSE Limited and is also a SEBI-registered Category I Merchant Banker. BOBCAPS is a wholly owned subsidiary of Bank of Baroda which has its various subsidiaries engaged in the businesses of stock broking, lending, asset management, life insurance, health insurance and wealth management, among others.

BOBCAPS's activities have neither been suspended nor has it defaulted with any stock exchange authority with whom it has been registered in the last five years. BOBCAPS has not been debarred from doing business by any stock exchange or SEBI or any other authority. No disciplinary action has been taken by any regulatory authority against BOBCAPS affecting its equity research analysis activities.

BOBCAPS has obtained registration as a Research Entity under SEBI (Research Analysts) Regulations, 2014, having registration No.: INH000000040 valid till 03 February 2020. BOBCAPS is also a SEBI-registered intermediary for the broking business having SEBI Single Registration Certificate No.: INZ000159332 dated 20 November 2017.

BOBCAPS prohibits its analysts, persons reporting to analysts, and members of their households from maintaining a financial interest in the securities or derivatives of any companies that the analysts cover. Additionally, BOBCAPS prohibits its analysts and persons reporting to analysts from serving as an officer, director, or advisory board member of any companies that the analysts cover.

Our salespeople, traders, and other professionals may provide oral or written market commentary or trading strategies to our clients that reflect opinions contrary to the opinions expressed herein, and our proprietary trading and investing businesses may make investment decisions that are inconsistent with the recommendations expressed herein. In reviewing these materials, you should be aware that any or all of the foregoing, among other things, may give rise to real or potential conflicts of interest. Additionally, other important information regarding our relationships with the company or companies that are the subject of this material is provided herein.

This material should not be construed as an offer to sell or the solicitation of an offer to buy any security in any jurisdiction where such an offer or solicitation would be illegal. We are not soliciting any action based on this material. It is for the general information of BOBCAPS's clients. It does not constitute a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual clients. Before acting on any advice or recommendation in this material, clients should consider whether it is suitable for their particular circumstances and, if necessary, seek professional advice.

The price and value of the investments referred to in this material and the income from them may go down as well as up, and investors may realize losses on any investments. Past performance is not a guide for future performance, future returns are not guaranteed and a loss of original capital may occur. BOBCAPS does not provide tax advice to its clients, and all investors are strongly advised to consult with their tax advisers regarding any potential investment in certain transactions — including those involving futures, options, and other derivatives as well as non-investment-grade securities — that give rise to substantial risk and are not suitable for all investors. The material is based on information that we consider reliable, but we do not represent that it is accurate or complete, and it should not be relied on as such. Opinions expressed are our current opinions as of the date appearing on this material only. We endeavour to update on a reasonable basis the information discussed in this material, but regulatory, compliance, or other reasons may prevent us from doing so.

We and our affiliates, officers, directors, and employees, including persons involved in the preparation or issuance of this material, may from time to time have “long” or “short” positions in, act as principal in, and buy or sell the securities or derivatives thereof of companies mentioned herein and may from time to time add to or dispose of any such securities (or investment). We and our affiliates may act as market makers or assume an underwriting commitment in the securities of companies discussed in this document (or in related investments), may sell them to or buy them from customers on a principal basis, and may also perform or seek to perform investment banking or advisory services for or relating to these companies and may also be represented in the supervisory board or any other committee of these companies.

For the purpose of calculating whether BOBCAPS and its affiliates hold, beneficially own, or control, including the right to vote for directors, one per cent or more of the equity shares of the subject company, the holdings of the issuer of the research report is also included.

BOBCAPS and its non-US affiliates may, to the extent permissible under applicable laws, have acted on or used this research to the extent that it relates to non-US issuers, prior to or immediately following its publication. Foreign currency denominated securities are subject to fluctuations in exchange rates that could have an adverse effect on the value or price of or income derived from the investment. In addition, investors in securities such as ADRs, the value of which are influenced by foreign currencies, effectively assume currency risk. In addition, options involve risks and are not suitable for all investors. Please ensure that you have read and understood the Risk disclosure document before entering into any derivative transactions.

In the US, this material is only for Qualified Institutional Buyers as defined under rule 144(a) of the Securities Act, 1933. No part of this document may be distributed in Canada or used by private customers in the United Kingdom.

No part of this material may be (1) copied, photocopied, or duplicated in any form by any means or (2) redistributed without BOBCAPS’s prior written consent.

#### **Other disclosures**

BOBCAPS does not have any financial interest in the subject company. BOBCAPS does not have actual/beneficial ownership of one per cent or more securities in the subject company at the end of the month immediately preceding the date of publication of this report.

BOBCAPS is not engaged in any market making activities for the subject company.

BOBCAPS or its associates may have material conflict of interest at the time of publication of this research report.

BOBCAPS’s associates may have financial interest in the subject company. BOBCAPS’s associates may hold actual / beneficial ownership of one per cent or more securities in the subject company at the end of the month immediately preceding the date of publication of this report.

BOBCAPS or its associates may have managed or co-managed a public offering of securities for the subject company or may have been mandated by the subject company for any other assignment in the past 12 months.

BOBCAPS may have received compensation from the subject company in the past 12 months. BOBCAPS may from time to time solicit or perform investment banking services for the subject company. BOBCAPS or its associates may have received compensation from the subject company in the past 12 months for services in respect of managing or co-managing public offerings, corporate finance, investment banking or merchant banking, brokerage services or other advisory services in a merger or specific transaction. BOBCAPS or its associates may have received compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company in the past 12 months.